Tolerability of oral pamidronate in elderly patients with osteoporosis and other metabolic bone diseases

Current Therapeutic Research - Clinical and Experimental

Volumn 57, Issue 2, 1996, Pages 123-130

  Spivacow, Francisco R ^a,d   Zanchetta, José R ^a   Kerzberg, Eduardo M ^a   Frigeri, Adriana ^b   Fiasché, Roxana ^b   Roldán, Emilio J A ^c  

^a HOSPITAL RAMOS MEJÍA   (Argentina)

^b Department of Hematology   (Argentina)

^c Gador SA   (Argentina)

^d Instituto de Investigaciones Metabolicas   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

PAMIDRONIC ACID;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ARTICLE; CLINICAL TRIAL; CONSTIPATION; DROWSINESS; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; GASTRITIS; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; METABOLIC BONE DISEASE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; PRIORITY JOURNAL;

EID: 0029862962     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(96)80006-3     Document Type: Article

References (14)

1. Harinck HIJ, Papapoulos SE, Blanksma HJ, et al. Paget's disease of bone: Early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD). BMJ. 1987;295:1301-1305.
2. van Breukelen FJM, Bijvoet OLM, Frijlink WB, et al. Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: Observations on regulation of serum calcium. Calcif Tissue Int. 1982;34:321-327.
3. van Holten-Verzantvoort AT, Bijvoet OLM, Cleton FJ, et al. Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. Lancet. 1987;2:983-985.
4. Fromm GA, Vega E, Plantalech L, et al. Differential action of pamidronate on trabecular and cortical bone in women with involutional osteoporosis. Osteoporosis Int. 1991;1:129-133.
5. Foti R, Martorana U, Broggini M. Long-term tolerability of nasal spray formulation of salmon calcitonin. Curr Ther Res. 1995;56:429-435.
6. Mautalen CA, Casco CA, Gonzalez D, et al. Side effects of disodium aminohydroxypropylidene diphosphonate (APD) during treatment of bone diseases. BMJ. 1984;288:828-829.
7. Nagant de Deuxchaisnes C, Rombouts-Lindesmans C, Huaux JP, et al. Treatment of Paget's disease with the bisphosphonate APD. A biological and radiological study. In: Donath A, Curvoisier B, eds. Diphosphonates and Bone. Geneva: Medicine et Hygiene; 1982:303-327.
8. Coleman RE, Dirix LY, Dodwell D, et al. Phase I/II evaluation of effervescent and enteric coated oral pamidronate for bone metastases. Eur J Cancer. 1991;27:945-946.
9. Fleisch H. Bisphosphonate in Bone Disease. From the Laboratory to the Patient. 1st ed. Berne: Stampfli Co; 1993.
10. Fromm GA, Vega E, Galich AM, et al. Side effects verified during the treatment of 228 cases of involutional osteoporosis with pamidronate. Bone Miner. 1992;17(Suppl):S17. Abstract.
11. Lufkin EG, Argueta R, Whitaker MD, et al. Pamidronate: An unrecognized problem in gastrointestinal tolerability. Osteoporosis Int. 1994;4:320-322.
12. Francis RM. Oral bisphosphonates in the treatment of osteoporosis: A review. Curr Ther Res. 1995;56:831-851.
13. Adami A, Mian M, Gatti P, et al. Effects of two oral doses of alendronate in the treatment of Paget's disease of bone. Bone. 1994;15:415-417.
14. Adami S, Bhalla AK, Dorizzi R, et al. The acute phase response after bisphosphonate administration. Calcif Tissue Int. 1987;41:326-331.